Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel Free CRDF Stock Alerts

Cardiff Oncology (CRDF) Competitors

Cardiff Oncology logo
$1.31 -0.04 (-2.96%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$1.34 +0.03 (+2.21%)
As of 07/14/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CRDF vs. AMRN, INDP, FATE, LRMR, and IMRX

Should you buy Cardiff Oncology stock or one of its competitors? MarketBeat compares Cardiff Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiff Oncology include Amarin (AMRN), Indaptus Therapeutics (INDP), Fate Therapeutics (FATE), Larimar Therapeutics (LRMR), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry.

How does Cardiff Oncology compare to Amarin?

Amarin (NASDAQ:AMRN) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Amarin has a net margin of -15.51% compared to Cardiff Oncology's net margin of -8,527.43%. Amarin's return on equity of -2.99% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-15.51% -2.99% -2.07%
Cardiff Oncology -8,527.43%-95.51%-71.47%

Cardiff Oncology has a consensus target price of $7.50, suggesting a potential upside of 472.52%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, Amarin had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 4 mentions for Amarin and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Amarin's score of 0.43 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amarin
0 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cardiff Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amarin has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Amarin has higher revenue and earnings than Cardiff Oncology. Amarin is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$213.65M1.41-$38.80M-$0.65N/A
Cardiff Oncology$590K151.80-$45.85M-$0.67N/A

22.3% of Amarin shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Amarin beats Cardiff Oncology on 10 of the 17 factors compared between the two stocks.

How does Cardiff Oncology compare to Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 472.52%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

7.1% of Indaptus Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Indaptus Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Indaptus Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A
Cardiff Oncology$590K151.80-$45.85M-$0.67N/A

In the previous week, Indaptus Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Indaptus Therapeutics and 2 mentions for Cardiff Oncology. Indaptus Therapeutics' average media sentiment score of 1.58 beat Cardiff Oncology's score of 0.94 indicating that Indaptus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Indaptus Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Cardiff Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Indaptus Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -1,030.07% -299.69%
Cardiff Oncology -8,527.43%-95.51%-71.47%

Summary

Cardiff Oncology beats Indaptus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cardiff Oncology compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Fate Therapeutics has a net margin of -2,056.79% compared to Cardiff Oncology's net margin of -8,527.43%. Fate Therapeutics' return on equity of -58.89% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Fate Therapeutics-2,056.79% -58.89% -39.39%
Cardiff Oncology -8,527.43%-95.51%-71.47%

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by insiders. Comparatively, 8.5% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cardiff Oncology has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fate Therapeutics$6.32M55.18-$136.32M-$1.09N/A
Cardiff Oncology$590K151.80-$45.85M-$0.67N/A

Fate Therapeutics has a beta of 2.51, suggesting that its share price is 151% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Fate Therapeutics currently has a consensus price target of $5.13, indicating a potential upside of 71.40%. Cardiff Oncology has a consensus price target of $7.50, indicating a potential upside of 472.52%. Given Cardiff Oncology's higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Fate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fate Therapeutics
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

In the previous week, Fate Therapeutics had 5 more articles in the media than Cardiff Oncology. MarketBeat recorded 7 mentions for Fate Therapeutics and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Fate Therapeutics' score of 0.67 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fate Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cardiff Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Fate Therapeutics beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Larimar Therapeutics?

Cardiff Oncology (NASDAQ:CRDF) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Larimar Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Cardiff Oncology's return on equity of -95.51% beat Larimar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-8,527.43% -95.51% -71.47%
Larimar Therapeutics N/A -134.14%-96.00%

Cardiff Oncology has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Cardiff Oncology currently has a consensus target price of $7.50, indicating a potential upside of 472.52%. Larimar Therapeutics has a consensus target price of $12.71, indicating a potential upside of 241.78%. Given Cardiff Oncology's higher probable upside, research analysts clearly believe Cardiff Oncology is more favorable than Larimar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Larimar Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.09

Cardiff Oncology has higher revenue and earnings than Larimar Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$590K151.80-$45.85M-$0.67N/A
Larimar TherapeuticsN/AN/A-$165.67M-$2.06N/A

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Larimar Therapeutics had 6 more articles in the media than Cardiff Oncology. MarketBeat recorded 8 mentions for Larimar Therapeutics and 2 mentions for Cardiff Oncology. Larimar Therapeutics' average media sentiment score of 1.07 beat Cardiff Oncology's score of 0.94 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cardiff Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Larimar Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Cardiff Oncology and Larimar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cardiff Oncology compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

In the previous week, Immuneering had 4 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for Immuneering and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Immuneering's score of 0.93 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuneering
0 Very Positive mention(s)
4 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cardiff Oncology
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cardiff Oncology has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuneeringN/AN/A-$56.03M-$1.17N/A
Cardiff Oncology$590K151.80-$45.85M-$0.67N/A

Immuneering has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Immuneering's return on equity of -31.93% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuneeringN/A -31.93% -29.92%
Cardiff Oncology -8,527.43%-95.51%-71.47%

Immuneering presently has a consensus target price of $16.57, indicating a potential upside of 218.07%. Cardiff Oncology has a consensus target price of $7.50, indicating a potential upside of 472.52%. Given Cardiff Oncology's higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Immuneering.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuneering
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Cardiff Oncology
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Immuneering has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 8.5% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Immuneering beats Cardiff Oncology on 9 of the 16 factors compared between the two stocks.

Get Cardiff Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRDF vs. The Competition

Export
MetricCardiff OncologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$92.30M$3.68B$6.85B$12.44B
Dividend YieldN/A2.19%2.68%8.43%
P/E Ratio-1.9620.9827.0424.38
Price / Sales151.80311.16524.2592.59
Price / CashN/A143.6648.5959.36
Price / Book1.968.5410.806.33
Net Income-$45.85M$23.83M$3.59B$331.02M
7 Day Performance4.80%-2.77%-1.46%-0.33%
1 Month Performance-7.75%5.85%2.82%-1.29%
1 Year Performance-68.20%52.15%28.59%21.30%

Cardiff Oncology Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRDF
Cardiff Oncology
3.7495 of 5 stars		$1.31
-3.0%		$7.50
+472.5%		-68.3%$92.30M$590KN/A20
AMRN
Amarin
1.803 of 5 stars		$15.73
-3.9%		N/A-10.7%$343.26M$213.65MN/A360
INDP
Indaptus Therapeutics
1.102 of 5 stars		$2.85
-5.9%		N/A-79.1%$343.12MN/AN/A6
FATE
Fate Therapeutics
3.6904 of 5 stars		$2.99
+2.4%		$5.13
+71.4%		+162.3%$340.35M$6.65MN/A550
LRMR
Larimar Therapeutics
4.3578 of 5 stars		$3.29
+0.9%		$12.71
+286.5%		+7.8%$338.66MN/AN/A30

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CRDF) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel